Ramon Sastre
General Practice · Hialeah, FLNPI 1518910918
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $887 of the $987 with a category attached, or 89.9%. 12 manufacturers reported payments, led by Astellas Pharma US Inc at 24.8% of the total. Reporting peaked in 2022 at $455 and has fallen 89.6% since, to $47 in 2023.
Across 33 payments — averaging $29.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$245
- Johnson & Johnson$167
- AstraZeneca$147
- Novo Nordisk$144
- Boehringer Ingelheim$66
- Bayer$51
- plus $167 from 6 others
Across 315 payments — averaging $2484.44 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$447K
- Vanda Pharmaceuticals Inc.$126K
- Akebia Therapeutics Inc$101K
- Bausch Health US, LLC$73K
- Pfizer$35K
- Eli Lilly$878
What the payments were for
- Food & beverage$88790%
- Education$10010%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 8 | $245 |
| Johnson & Johnson | 4 | $167 |
| AstraZeneca | 3 | $147 |
| Novo Nordisk | 2 | $144 |
| Boehringer Ingelheim | 4 | $66 |
| Bayer | 2 | $51 |
| AbbVie | 3 | $44 |
| Lilly USA, LLC | 2 | $37 |
| Amarin Pharma, Inc. | 2 | $36 |
| Abbott | 1 | $22 |
| Cardiovascular Systems Inc. | 1 | $15 |
| Medtronic | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$987 in reported general payments places this provider in the 80th percentile of 6,901 general practice providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 56 | $70,489 |
| XareltoRivaroxaban | 27 | $37,290 |
| TrulicityDulaglutide | 16 | $24,156 |
| MounjaroTirzepatide | 14 | $14,203 |
| SynthroidLevothyroxine Sodium | 15 | $2,064 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 65 | $2,028 |
| Omeprazole | 129 | $1,500 |
| FenofibrateFenofibrate,micronized | 64 | $1,496 |
| Atorvastatin Calcium | 155 | $1,351 |
| Tamsulosin Hcl | 113 | $1,237 |
| Rosuvastatin Calcium | 85 | $1,106 |
| Neomycin-Polymyxin-HcNeomycin/Polymyxin B/Hydrocort | 13 | $1,069 |
| Levothyroxine Sodium | 99 | $1,056 |
| Wixela InhubFluticasone Propion/Salmeterol | 14 | $995 |
| Fluticasone Propionate | 65 | $844 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $37 | $38,35930 claims |
| Johnson & JohnsonXarelto | $167 | $37,29027 claims |
| AbbVieSynthroid | $44 | $2,06415 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 6,901 general practice providers in Florida.
Other general practice in Hialeah
- Daniel BasultoHialeah$31K
- Jose GonzalezHialeah$21K
- Julian MarquezHialeah$18K
- Robert VogelPalm Beach Gardens$1M
- Bruce OuelletteWest Palm Beach$724K
- Caley CasteleinMiami Beach$586K
- Sarah JockinTampa$308K
- Mario RomeroSarasota$275K
- Robert RitterJupiter$233K
- Robert AltharPensacola$231K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.